What's happening in the industry

Keytruda approved for any solid tumor with a specific genetic marker read on...

BMS, Qiagen to develop gene expression profiles for immuno-oncology therapies read on...

Up to 50% of Aetna, UnitedHealth Group and Anthem reimbursements go to value-based contracts; clinical laboratories must implement value-based strategies to remain competitive read on...

Comprehensive genomic profiling helps detect patients with ovarian cancer likely to benefit from PARP inhibition read on...

Loxo Oncology breakthrough therapy Larotrectinib demonstrates 76 percent confirmed objective response rate in TRK fusion adult and pediatric cancers as presented at ASCO read on...

Naval Medical Center study reveals more than one-third of genetic tests are misordered; clinical laboratories critical to improving lab test utilization read on...

Foundation Medicine, Flatiron Health show utility of clinico-genomic database at ASCO read on...

Guardant Health, Foundation Medicine to participate in Cure-One N1 registry read on...

New blood test could see personalised prostate cancer treatment read on...

NICE, Roche reach deal on breast cancer drug read on...

PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer read on...

FDA approves Roche’s lung cancer companion diagnostic read on...

Immunotherapy drug effective for metastatic triple negative breast cancer read on...

Combined immunotherapy could help control melanoma that has spread to the brain read on...

Heidelberg cancer collaboration enables targeted and comprehensive molecular tumor profiling read on...

Next-generation cancer drugs boost immunotherapy responses read on...

Thermo Fisher announces the expansion of two next-generation sequencing assays that align with the most recent published evidence of cancer research read on...

Patient selection vital in ensuring improved response to PD-1, PD-L1 inhibitors in NSCLC read on...

Peregrine Pharmaceuticals presents preliminary correlative analysis of PD-L1 expression from SUNRISE Trial at ASCO 2017 read on...

PD-L1 checkpoint player Merck KGaA dives into next-gen work with F-star collaboration read on...

CancerLinQ partners with FDA for precision medicine studies read on...

Precision Medicine Initiative's All of Us research program enrolls beta testers read on...

ASCO: Philips proclaims a pair of precision medicine partnerships read on...

Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene read on...

Myriad Genetics confirms BRACAnalysis CDx test identified patients with metastatic breast cancer who benefited from treatment with Olaparib in Phase 3 OlympiAD study read on...

AstraZeneca's Lynparza slows breast cancer caused by BRCA mutations by 42% read on...

Sequencing panel improves mutation analysis in solid malignancies read on...

Exploratory analysis of the Phase I/II CHRYSALIS study of gilteritinib demonstrates first molecular response to FLT3 inhibitor in acute myeloid leukemia read on...

Boston Healthcare Associates and Data Information Intelligence announce global life sciences data commercialization partnership read on...

Norwegian team plans to debut digital PCR-based urinary bladder cancer test by year end read on...

MSKCC researchers debut high-intensity liquid biopsy method developed with Grail read on...

Prostate cancer trial stuns researchers: 'It's a once in a career feeling' read on...

Bristol-Myers, leading immuno-oncology in liver cancer, nabs Opdivo 'priority' tag and nears Bayer showdown read on...

Color's low-cost hereditary cancer risk panel garners in-network status with several insurers read on...

How Trump can curb runaway drug prices read on...

What you might have missed

Data for life: new partnership with IBMS is another step forward in accelerating market penetration
Leave no patient behind: how the FDA approval of Keytruda for specific biomarkers will put laboratory testing in the front line
Better Testing Ebook: how testing can play a central role in achieving the optimal economic model
FDA has approved Philips' digital pathology solution as a primary diagnosis tool – it’s about time